Prevalence and predictors of over-the-counter medication use among pregnant women: a cross-sectional study in the Netherlands

BMC Public Health

Eelko Hak¹  Jan G Aarnoudse²  Janna M Munster²  Elise J Smolders¹  Gwenny MPJ Verstappen¹ 

[1] University of Groningen, University Center for Pharmacy, PharmacoEpidemiology&PharmacoEconomics, Antonius Deusinglaan 1, 9713 AV, Groningen, The Netherlands;Department of Obstetrics and Gynecology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, Groningen, 9713GZ, The Netherlands

关键词: Prediction model;    Epidemiology;    The Netherlands;    Pregnancy;    OTC-medication;   

Others  :  1162494
DOI  :  10.1186/1471-2458-13-185

 received in 2012-04-25, accepted in 2013-02-08,  发布年份 2013

【 摘 要 】

Background

Over-the-counter-medication (OTC-medication) use during pregnancy can be potentially harmful for the fetus. To successfully counsel the patient it is important to know if the patient is at risk. In this study possible predictors for OTC-medication use were identified and a model was designed to predict OTC-medication use during pregnancy.

Methods

We performed a post-hoc analysis on data collected for a clustered clinical trial to study a screening strategy for Query fever. Pregnant women under supervision of a midwife were eligible for inclusion. These women filled out questionnaires during their pregnancy and post-partum. These questionnaires were used to determine the prevalence and to select possible predictors for OTC-medication use. These predictors were included in a prediction model using multivariate analysis. The discrimination and calibration of the model were assessed with Receiver Operating Characteristic analysis and the Hosmer and Lemeshow test.

Results

Of the 1348 women enrolling in the clustered clinical trial, we included 1246 women in this analysis. The prevalence of OTC-medication use was 12.5%. The predictors for OTC-medication use in our cohort were: nulliparity, use of prescription medication, the presence of a comorbidity, Body Mass Index between 26 and 30 kg/m² and General Practitioner visits. These predictors were used to design a prediction model for OTC-medication use. The area under the Receiver Operating Characteristic-curve of the prediction model was 0.667 (95% CI 0.620-0.714 P<0.001) and the predictive probabilities ranged from 6.6% to 57.4%. The Hosmer and Lemeshow goodness-of-fit test indicated good calibration of the model (P = 0.640).

Conclusion

It is possible to indicate women at risk for OTC-medication use during pregnancy, using five maternal characteristics that independently contribute to the prediction model. The predictors are easy to estimate and the model is easy to implement in daily practice.

【 授权许可】

   
2013 Verstappen et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Koren G, Florescu A, Moldovan Costei A, Boskovic R, More ME: Nonsteroidal Antiinflammatory drugs during third trimester and the risk of premature closure of the ductus arteriosus: a meta-analysis. Ann Pharmacother 2006, 40:824-829.
• [2]Nakhai-Pour HR, Broy P, Sheehy O, Bérard A: Use of nonaspirinnonsteroidal anti-inflammatory drugs during pregnancy and the risk of spontaneous abortion. CMAJ 2011, 183(supl 15):1713-1720. doi:10.1503/CMAJ.110454
• [3]WINAp Geneesmiddel Informatie: Standaarden voor Zelfzorg. Den Haag; 2008.
• [4]Glover DD, Amonkar M, Rybeck BF, Tracy TS: Prescription, over-the-counter, and herbal medicine use in a rural, obstetric population. Am J ObstetGynecol 2003, 188:1039-1045.
• [5]Rubin JD, Ferencz D, Lofferedo C, The Balitmore-Washington infant study group: Use of prescription and non-prescription drugs in pregnancy. J ClinEpidemiol 1993, 46:581-589.
• [6]De Vigan C, De Walle HEK, Cordier S, Goujard J, Knill-Jones R, Aymé S, Calzolari E, Bianchi F: Therapeutic drug use during pregnancy: a comparison in four European countries. J ClinEpidemiol 1999, 52:977-982.
• [7]Schirm E, Meijer WM, Tobi H, De Jong-van den Berg LTW: Drug use by pregnant women and comparable non-pregnant women in the Netherlands with reference to the Australian classification system. Eur J ObstetGynecol and ReprodBiol 2004, 114:182-188.
• [8]Munster JM, Leenders ACAP, van der Hoek W, Schneeberger PM, Rietveld A, Riphagen-Dalhuisen J, Stolk RP, Hamilton CJ, de Vries E, Meekelenkamp J, Lo-Ten-Foe JR, Timmer A, De Jong-van den Berg LTW, Aarnoudse JG, Hak E: Cost-effectiveness of a screening strategy for Q fever among pregnant women in risk areas: a clustered randomized controlled trail. BMC Womens Health 2010, 10:32. BioMed Central Full Text
• [9]WHO Collaborating Centre for Drug Statistics Methodology: ATC classification index with DDDs. Oslo; 2011.
• [10]WINap Geneesmiddel Informatie en Wetenschapswinkel Groningen: Zelfzorgmedicijnen tijdens zwangerschap en borstvoeding; wat kan ik doen, wat mag ik slikken?. Groningen; 2004.
• [11]Moons KGM, Royston P, Vergouwe Y, Grobbee DE, Altman DG: Prognosis and prognostic research: what, why and how? BMJ 2009, 338:1317-1320.
• [12]Werler MW, Mitchell AA, Hernandez-Diaz S, Honein MA: Use of over-the-counter medications during pregnancy. Am J ObstetGynecol 2005, 193:771-7.
• [13]Cleary BJ, Butt H, Strawbridge JD, Gallagher PJ, Fahey T, Murphy DJ: Medication use in early pregnancy-prevalence and determinants of use in a prospective cohort of women. Pharmacoepidemiol Drug Saf 2010, 19:408-417.
• [14]Bonassi S, Magnani M, Calvi A, Repetto E, Puglisi P, Pantarotto F, Lazzaroni F: Factors related to drug consumption during pregnancy. Acta Obstet Gynecol Scand 1994, 73:535-540.
• [15]Bercaw J, Maheshwari B, Sangi-Haghpeykar H: The use during pregnancy of prescription, over-the-counter, and alternative medications among Hispanic women. Birth 2010, 37:211-218.
• [16]de Jong-van den Berg LTW, Waardenburg C: Geneesmiddelengebruik tijdens zwangerschap. Groningen: STYX; 1991.